GlassScriptPhysician profile
Katherine Regling
NPI 1174940548
$81,495.21
in general payments reported to CMS, 2019-2025
8 companies · $61.92 in 2025
The $61.92 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $26K · 2021: $55K · 2022: $120 · 2023: $143 · 2024: $59.66 · 2025: $61.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $264.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $77,376.15 | 2020-2023 | |
| Genzyme Corporation | $3,731.25 | 2021-2025 | |
| Genentech USA, INC. | $248.79 | 2019-2023 | Hemlibra |
| Takeda Pharmaceuticals U.S.A., INC. | $61.19 | 2022-2024 | Cuvitru |
| Pfizer INC. | $27.83 | 2024 | |
| Octapharma USA, INC. | $25.63 | 2025 | Nuwiq |
| Emmaus Medical, INC. | $13.30 | 2025 | Endari |
| Shire North American Group INC | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Regling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.